Citadel Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $248K | Buy |
178,200
+31,500
| +21% | +$43.3K | ﹤0.01% | 10932 |
|
|
2025
Q4 | $236K | Buy |
146,700
+41,000
| +39% | +$85.8K | ﹤0.01% | 10683 |
|
|
2025
Q3 | $289K | Buy |
105,700
+65,100
| +160% | +$217K | ﹤0.01% | 10472 |
|
|
2025
Q2 | $148K | Buy |
40,600
+3,600
| +10% | +$9.89K | ﹤0.01% | 10970 |
|
|
2025
Q1 | $71K | Buy |
37,000
+13,600
| +58% | +$27.8K | ﹤0.01% | 11895 |
|
|
2024
Q4 | $44.5K | Sell |
23,400
-104,100
| -82% | -$181K | ﹤0.01% | 12510 |
|
|
2024
Q3 | $168K | Buy |
127,500
+35,700
| +39% | +$47.7K | ﹤0.01% | 10403 |
|
|
2024
Q2 | $93.6K | Sell |
91,800
-43,300
| -32% | -$53.5K | ﹤0.01% | 11006 |
|
|
2024
Q1 | $247K | Sell |
135,100
-4,400
| -3% | -$7.03K | ﹤0.01% | 9885 |
|
|
2023
Q4 | $173K | Buy |
139,500
+11,200
| +9% | +$11.4K | ﹤0.01% | 10167 |
|
|
2023
Q3 | $146K | Buy |
128,300
+18,900
| +17% | +$24.3K | ﹤0.01% | 10400 |
|
|
2023
Q2 | $100K | Buy |
109,400
+34,600
| +46% | +$33.4K | ﹤0.01% | 10937 |
|
|
2023
Q1 | $41.9K | Sell |
74,800
-14,400
| -16% | -$11K | ﹤0.01% | 12385 |
|
|
2022
Q4 | $51.5K | Buy |
89,200
+14,100
| +19% | +$4.42K | ﹤0.01% | 12099 |
|
|
2022
Q3 | $24K | Sell |
75,100
-81,100
| -52% | -$31.8K | ﹤0.01% | 11995 |
|
|
2022
Q2 | $55K | Sell |
156,200
-301,500
| -66% | -$127K | ﹤0.01% | 11863 |
|
|
2022
Q1 | $329K | Buy |
457,700
+405,700
| +780% | +$868K | ﹤0.01% | 10374 |
|
|
2021
Q4 | $118K | Sell |
52,000
-20,000
| -28% | -$54.5K | ﹤0.01% | 12540 |
|
|
2021
Q3 | $207K | Sell |
72,000
-5,500
| -7% | -$15.7K | ﹤0.01% | 11914 |
|
|
2021
Q2 | $294K | Sell |
77,500
-31,200
| -29% | -$105K | ﹤0.01% | 11318 |
|
|
2021
Q1 | $368K | Sell |
108,700
-21,400
| -16% | -$77.1K | ﹤0.01% | 10370 |
|
|
2020
Q4 | $364K | Buy |
130,100
+71,300
| +121% | +$208K | ﹤0.01% | 8733 |
|
|
2020
Q3 | $148K | Buy |
58,800
+8,300
| +16% | +$72.8K | ﹤0.01% | 9009 |
|
|
2020
Q2 | $686K | Buy |
50,500
+26,700
| +112% | +$276K | ﹤0.01% | 6509 |
|
|
2020
Q1 | $180K | Buy |
+23,800
| New | +$185K | ﹤0.01% | 8113 |
|
|
2018
Q4 | – | Sell |
-21,700
| Closed | -$192K | – | 9029 |
|
|
2018
Q3 | $192K | Buy |
21,700
+7,500
| +53% | +$67.1K | ﹤0.01% | 8239 |
|
|
2018
Q2 | $142K | Sell |
14,200
-600
| -4% | -$6.01K | ﹤0.01% | 8096 |
|
|
2018
Q1 | $141K | Sell |
14,800
-400
| -3% | -$5.59K | ﹤0.01% | 7570 |
|
|
2017
Q4 | $226K | Sell |
15,200
-800
| -5% | -$13.3K | ﹤0.01% | 6923 |
|
|
2017
Q3 | $315K | Buy |
+16,000
| New | +$246K | ﹤0.01% | 5993 |
|
|
2016
Q2 | – | Sell |
-16,300
| Closed | -$147K | – | 6773 |
|
|
2016
Q1 | $147K | Buy |
+16,300
| New | +$132K | ﹤0.01% | 5841 |
|
|
2015
Q4 | – | Sell |
-1,900
| Closed | -$18K | – | 8678 |
|
|
2015
Q3 | $18K | Sell |
1,900
-7,600
| -80% | -$69.7K | ﹤0.01% | 8222 |
|
|
2015
Q2 | $98K | Buy |
+9,500
| New | +$81K | ﹤0.01% | 7093 |
|
Other funds holding AKBA
VCM
VPM
Citadel Advisors's AKBA Position: Q1 2026 in Review
Citadel Advisors reduced its Akebia Therapeutics (AKBA) stake by 70% in Q1 2026, selling an estimated $4.5M and leaving 1,390,067 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6131.
Citadel Advisors first reported a position in AKBA in Q1 2014 and has held it in 38 quarters since. The position peaked at $8.76M in Q3 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Citadel Advisors held 1,390,067 shares of Akebia Therapeutics worth $1.93M as of Q1 2026.
- Citadel Advisors sold 3,275,470 Akebia Therapeutics shares in Q1 2026, an estimated $4.5M.
- Akebia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6131 holding.
- Citadel Advisors first reported a position in Akebia Therapeutics in Q1 2014 and has held it in 38 quarters since.
- Citadel Advisors's Akebia Therapeutics position peaked at $8.76M in Q3 2018.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.